Exchange Traded Concepts LLC Has $859,000 Stock Holdings in NovoCure Limited (NASDAQ:NVCR)

Exchange Traded Concepts LLC cut its position in NovoCure Limited (NASDAQ:NVCR - Free Report) by 40.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,811 shares of the medical equipment provider's stock after selling 19,616 shares during the quarter. Exchange Traded Concepts LLC's holdings in NovoCure were worth $859,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. FMR LLC grew its position in NovoCure by 0.6% in the 3rd quarter. FMR LLC now owns 16,232,008 shares of the medical equipment provider's stock valued at $253,706,000 after buying an additional 90,422 shares during the last quarter. Nordwand Advisors LLC lifted its stake in shares of NovoCure by 100.0% in the 3rd quarter. Nordwand Advisors LLC now owns 3,029,824 shares of the medical equipment provider's stock worth $47,356,000 after acquiring an additional 1,514,824 shares during the period. Geode Capital Management LLC boosted its holdings in shares of NovoCure by 1.3% in the third quarter. Geode Capital Management LLC now owns 2,405,257 shares of the medical equipment provider's stock valued at $37,601,000 after acquiring an additional 29,871 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of NovoCure by 10.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 907,999 shares of the medical equipment provider's stock worth $14,192,000 after acquiring an additional 84,606 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in NovoCure by 2.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 824,443 shares of the medical equipment provider's stock worth $12,886,000 after purchasing an additional 16,339 shares in the last quarter. 84.61% of the stock is owned by institutional investors and hedge funds.

NovoCure Stock Down 3.9 %

NovoCure stock traded down $0.99 during midday trading on Friday, hitting $24.52. 700,249 shares of the company were exchanged, compared to its average volume of 864,129. The company has a market cap of $2.65 billion, a PE ratio of -17.51 and a beta of 0.64. NovoCure Limited has a fifty-two week low of $11.70 and a fifty-two week high of $34.13. The company's fifty day moving average price is $27.81 and its 200-day moving average price is $21.11. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.49 and a quick ratio of 1.44.

NovoCure (NASDAQ:NVCR - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.06. The business had revenue of $155.10 million for the quarter, compared to analysts' expectations of $143.95 million. NovoCure had a negative return on equity of 41.48% and a negative net margin of 25.93%. The company's revenue was up 21.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.46) earnings per share. On average, research analysts predict that NovoCure Limited will post -1.3 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on NVCR. HC Wainwright reissued a "buy" rating and issued a $38.00 price target on shares of NovoCure in a report on Tuesday, January 14th. Piper Sandler raised their target price on NovoCure from $28.00 to $42.00 and gave the company an "overweight" rating in a report on Friday, December 13th. Wedbush reaffirmed a "neutral" rating and set a $29.00 price target on shares of NovoCure in a research note on Monday, January 13th. Finally, Evercore ISI upgraded shares of NovoCure from an "in-line" rating to an "outperform" rating and increased their price target for the company from $18.00 to $30.00 in a report on Monday, December 2nd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, NovoCure currently has a consensus rating of "Moderate Buy" and an average price target of $32.67.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.